20/20 Onsite

06/05/2026

When OCT, BCVA, IOP, visual fields, and fundus photography depend on trained personnel, calibrated equipment, and participant access, every logistics gap becomes a data risk.

This article breaks down how point-of-need ex*****on can help protect ocular endpoints, reduce trial friction, and support protocol adherence.

Read the full article: https://hubs.ly/Q04f3DqN0

06/03/2026

20/20 Onsite is heading to the World Orphan Drug Congress USA in Boston, June 9 to 11.

Sam Larberg and Keenan Siciliano will be attending and look forward to connecting with sponsors, CROs, advocacy leaders, and rare disease innovators working to bring new therapies closer to the patients who need them most.

For rare disease trials, patient access, retention, and specialized assessment logistics can become major barriers. That is where point-of-need ophthalmic assessments can help reduce patient burden while supporting protocol-adherent trial ex*****on.

Attending the congress? Reach out to Sam or Keenan to schedule time to connect or grab a time here: https://hubs.ly/Q04jYg4H0

05/28/2026

The FDA has approved the first digital therapeutic for amblyopia in over a decade, opening the door to VR-based binocular training, digital neurotherapy, and innovative vision games that engage both eyes simultaneously.

These breakthrough pediatric trials are exploring treatments that kids actually want to do. Clinical studies show children using VR-based therapy achieved 88% median adherence, compared to traditional patching, which often sees adherence below 50%.

But reaching families for enrollment? That's the real challenge.

20/20 Onsite meets families where they are:
Mobile clinics at schools and community centers
Kid-friendly assessment environments
Flexible scheduling that respects family routines
Refractive measurements, stereo testing, and compliance monitoring, on location

We make participation easy so families can stick with study schedules without long clinic trips.

Because breakthrough pediatric therapies deserve breakthrough enrollment strategies.

05/20/2026

Vision loss from Geographic Atrophy doesn't wait, and neither should innovation.

GA, the advanced dry form of AMD, is finally seeing a breakthrough as treatments emerge. From complement inhibitors to regenerative cell and gene therapy, the pipeline is promising.

But with ~16 GA trials competing for the same patient pool, finding qualified participants is the first challenge. Then comes retention.

That's where we come in.

20/20 Onsite brings two critical solutions:

Pre-screening expertise to identify eligible patients fast in a crowded landscape with overlapping inclusion/exclusion criteria.

Mobile OCT and retinal imaging eliminate travel barriers, ensuring participants stay enrolled, and imaging visits happen on schedule.

82% reduction in travel distance
9% dropout rate (vs 30% industry standard)
Quality ocular endpoint protection

GA trials need more than just participants; they need the right participants who stay through to completion.

Our mobile ophthalmic expertise ensures efficient enrollment and seamless imaging capture without burdening participants or compromising data quality.

Prepared to accelerate your GA study? Let's talk.
https://hubs.ly/Q04cN-Wm0

05/19/2026

For trials with ophthalmic endpoints, the risk is not just whether the trial is managed well. It is whether the endpoint is executed consistently, accurately, and accessibly at the point of need.

In our latest article, we break down what clinical trial management solutions often miss, and why specialized ophthalmic endpoint ex*****on matters for data quality, protocol adherence, and participant retention.

Read the full article: https://hubs.ly/Q04f1-0X0

05/15/2026

Thank you to everyone who connected with us at ARVO 2026.

It was great to spend the week with sponsors, CROs, and clinical research teams in Denver, and to give attendees an up-close look at our Mobile Vision Clinic and how point-of-need ophthalmic assessments are executed in real-world trials.

A few themes stood out in the conversations we had throughout the week:

• The gap between site and mobile capabilities is closing. As advanced delivery models gain traction, the conversation has shifted from simple screenings to bringing full site-level ophthalmic infrastructure to the patient to support increasingly complex protocols.

• Operational flexibility is now a survival metric. With site strain and a tightening ophthalmology workforce dominating conversations in Denver, the consensus was clear: trials that succeed will rely on deploy

We’re grateful for the conversations, the questions, and the opportunity to show what single-call accountability can look like in practice.

If we met at ARVO and you'd like to keep the conversation going, reach out to our team or book a call/protocol review here: https://hubs.ly/Q04gS6yG0

05/14/2026

Proud to support the 2026 Health Equity Trends Summit, bringing together leaders focused on advancing real, measurable progress in care access and outcomes.

At 20/20 Onsite, we see every day how reducing patient burden and meeting people where they are can change participation, retention, and results. Looking forward to the conversations ahead.

Learn more: https://hubs.ly/Q04dyF3B0

The 2026 Health Equity Trends Summit convenes leaders from government, health care, business, and community organizations at a critical moment for Massachusetts. Federal policies are reshaping access to coverage, funding, and even the data we rely on to understand and address health disparities. The...

05/12/2026

Myopia is the fastest-growing eye epidemic in the world, and trials need to keep pace.

By 2050, nearly half the global population is projected to be myopic, making myopia progression trials more critical than ever.

From low-dose atropine to red-light therapy and specialty contact lenses, myopia progression research is exploding. But reaching young participants and their families requires a different approach.

20/20 Onsite brings the clinic to them:
- Schools & universities
- Community centers
- Family-friendly locations

We make enrollment easy, visits convenient, and data collection seamless for accurate refractive measurements, axial length monitoring, and compliance tracking, all while reducing the burden on families and young participants.

With 100,000+ eye exams performed and an average Net Promoter Score of 95, we know how to keep young participants engaged.

Myopia won't wait. Your trial enrollment shouldn't either.

Let's bring your myopia study to the community: https://hubs.ly/Q04cNvy80

05/11/2026

Retinoblastoma, the most common eye cancer in children, often begins with signs that are easy to miss. Early detection changes outcomes entirely.

Advancing that detection takes more than science. It takes reliable, accessible ophthalmic assessments that reach patients when and where they’re needed.

This World Retinoblastoma Awareness Week, we’re proud to support the trials helping move that work forward, one patient, one endpoint at a time.

05/08/2026

A clinical trial is a promise.

A promise to turn "what if" into "what's next" for the patient who was told their condition was untreatable. For the family watching someone lose sight slowly.

This Healthy Vision Month, we're thinking about the pipeline. The trials running right now could change what blindness means in ten years. The patients enrolled in them who need the clinic to come to them, not the other way around.

Every trial we support is a step in that pipeline. Every participant who stays enrolled is data that moves medicine forward.

That's what point-of-need delivery protects. Not just a visit. A promise.

One call. Point-of-need. Protocol to patient. https://hubs.ly/Q04dyTrP0